Selank presents an unusual situation in the peptide landscape: it is an approved medication in one country (Russia), with clinical trial data published primarily in Russian-language journals, and yet it remains largely unknown to Western regulatory bodies. This creates an epistemic challenge that I want to address directly — the data exists, but its accessibility and the degree to which it has undergone international peer review require us to hold it with appropriate nuance.
At a Glance
Property Detail
Type Synthetic analog of endogenous peptide (tuftsin)
Amino acid count 7
Primary mechanism BDNF modulation, monoamine neurotransmitter regulation, immunomodulation
Evidence level Russian clinical trials, human studies; limited Western replication
Regulatory status Approved in Russia as anxiolytic/nootropic; not approved in US/EU
Route of administration Intranasal
Anti-doping (WADA 2026) Not named on the Prohibited List. Selank is registered in Russia, so the rule for non-approved substances arguably does not apply; athletes should get a ruling from their anti-doping organisation
What Is Selank?
Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1990s. It is an analog of tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) that is produced by enzymatic cleavage of the heavy chain of immunoglobulin G (IgG). The researchers extended the tuftsin sequence with a Pro-Gly-Pro tripeptide to enhance metabolic stability while retaining biological activity.

Tuftsin itself has well-documented immunomodulatory properties — it enhances phagocytosis, activates natural killer cells, and modulates cytokine production. Selank retains some of these immunomodulatory effects while adding anxiolytic and nootropic properties that are not characteristic of tuftsin alone.
Selank is registered in Russia as 0.15% nasal drops. The Russian label lists anxiety states in adults (including generalised anxiety, panic attacks, neurasthenia, asthenia, sleep disturbance and adjustment disorders) and the prevention and treatment of stress disorders (RLS product information).
Mechanism of Action
Primary Pathways
- BDNF Modulation: Selank has been shown to increase the expression of brain-derived neurotrophic factor (BDNF) in the hippocampus and prefrontal cortex. BDNF is the principal neurotrophin involved in synaptic plasticity, learning, and memory. It also plays a role in mood regulation, and low BDNF levels are associated with depression and anxiety disorders. Selank’s effect on BDNF is thought to underlie both its anxiolytic and nootropic properties.
- Monoamine Neurotransmitter Modulation: Studies have demonstrated that Selank influences the metabolism of serotonin, dopamine, and norepinephrine in the brain. Specifically, it has been shown to stabilize enkephalin levels and modulate the expression of genes involved in serotonin transport and metabolism. This mechanism is conceptually similar to conventional anxiolytic medications, but the peptide appears to achieve these effects without the sedation, dependence, or withdrawal associated with benzodiazepines.
- GABAergic Modulation: Selank appears to enhance GABAergic neurotransmission: the primary inhibitory neurotransmitter system in the brain. Unlike benzodiazepines, which act as positive allosteric modulators at the GABA-A receptor, Selank’s GABAergic effects appear to be indirect, mediated through its effects on neuropeptide signaling and gene expression rather than direct receptor binding.
- Immunomodulatory Effects: Consistent with its tuftsin heritage, Selank retains significant immunomodulatory properties. It has been shown to modulate the expression of inflammatory cytokines, enhance phagocytic activity, and influence the Th1/Th2 balance. This dual anxiolytic-immunomodulatory profile is unusual among therapeutic agents and may be particularly relevant in conditions where anxiety and immune dysregulation co-occur.
Research Assessment
What the Evidence Shows
Claimed Effect Evidence Level Key Studies Assessment
Anxiolytic effect in GAD and neurasthenia Russian clinical study Zozulia 2008 Promising (needs Western replication)
BDNF upregulation Animal studies Inozemtseva 2008 Strong mechanistic data
Immunomodulation Animal + human studies Uchakina 2008 Promising
Serotonin metabolism modulation Animal studies Semenova 2009 Preliminary
The main Russian clinical study compared selank (30 patients) with the benzodiazepine medazepam (32 patients) in generalised anxiety disorder and neurasthenia. The anxiolytic effects on the Hamilton, Zung and CGI scales were similar, and selank also showed anti-asthenic and mildly stimulating effects (Zozulia et al., 2008). The Russian label states that selank does not cause dependence.
The challenge is that much of this clinical trial data has been published in Russian-language journals and has not been replicated by independent Western research groups. This does not mean the data is invalid. Russian pharmaceutical research has a legitimate scientific tradition, and the Institute of Molecular Genetics is a respected institution. But the absence of independent international replication means we should hold the efficacy claims with appropriate epistemic humility.
What the Evidence Does Not Show
The long-term effects of Selank use have not been established in large-scale studies. The anxiolytic efficacy has not been demonstrated in Western clinical trial frameworks (randomized, double-blind, placebo-controlled trials with sample sizes that would satisfy FDA or EMA standards).
The nootropic effects, while reported in clinical studies and described by users, have not been characterized with the precision or rigor that would establish Selank as a proven cognitive enhancer.
Dosing
For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.
| Route | Dose range | Frequency | Duration | Source |
|---|---|---|---|---|
| Intranasal (registered use in Russia) | 2 drops of the 0.15% solution per nostril (roughly 900 mcg a day in total) | 3 times daily | 14 days, repeatable after 1-3 weeks | Label |
| Intranasal (community) | 200-300 mcg | 2-3 times daily | 4-6 weeks, often 1 month on, 1 month off | Anecdotal |
| Subcutaneous | 250–500 mcg | Daily | 4-6 weeks, 5 days on, 2 days off | Practice protocol |
The label gives drops, not micrograms; the microgram figure assumes a 50 microlitre drop (about 75 mcg per drop).
Selank is registered as a nasal medicine only in Russia, and its human evidence comes from small Russian studies of that formulation. Subcutaneous use has no human trial data. Outside Russia, selank is not approved (FDA, EMA, BfArM), and FDA lists it among compounding substances that may present significant safety risks. Nasal protocol: Selank Dosage: Nasal Spray Protocol and Cycling.
What People Report: What Works and What Doesn’t
Sources: the aggregated community data set (Peptide Protocol Wiki, 120 reports), the protocol and side-effect lists on Peptide DB, and the Russian comparison with medazepam in 62 patients (Zozulia 2008). Doses and their sources are in the protocol table.
Reported to work
- Less anxiety without sedation, the most common report: users describe a calm, clear-headed state. This fits the one Russian comparison, where selank’s anxiolytic effect was similar to medazepam’s.
- Clearer thinking under stress, building over 4-6 weeks of use.
- More even mood and less irritability.
Mixed or unclear
- Speed. Peptide DB describes nasal onset within 15-30 minutes; the larger community compilation puts noticeable anxiolytic effects at 1-2 weeks. Both may be true for different people and doses.
- Sleep: modest improvement, mainly when anxiety was what kept people awake.
- Nasal versus injected. Some prefer injection for consistent dosing, but the registered product and its human data are nasal.
- Whether cycling is needed. The community cycles (typically 4 weeks on, 4 off) to avoid tolerance; the Russian product information uses 14-day courses repeated after a break, and no study has tested tolerance.
Reported not to work, or disappointing
- Side effects are rarely described. The warning signs listed are unusual mood changes, more anxiety, severe headache and unexplained tiredness.
- Grey-market nasal sprays with no stated concentration, which make any dose estimate a guess.
- Independent replication: none. Every human result comes from small Russian studies.
What a properly designed trial would need to show: a randomised, double-blind trial outside Russia in generalised anxiety disorder, comparing nasal selank at the registered dose with placebo and an active comparator for 4-8 weeks, using standard anxiety scales and a withdrawal assessment at the end.
Safety and Side Effects
Known
In the Russian clinical experience, Selank has demonstrated a favorable safety profile. No significant adverse events, sedation, or dependence have been reported. Unlike benzodiazepines, Selank does not appear to impair cognitive function or psychomotor performance, and no withdrawal syndrome has been documented upon cessation.
Theoretical Concerns
The long-term neurological effects of exogenous BDNF modulation are not fully understood. While BDNF enhancement is generally considered neuroprotective, sustained upregulation of BDNF has theoretical implications for neural circuit remodeling that have not been studied over extended periods.
Contraindications
The Russian label lists hypersensitivity to the ingredients, pregnancy, breastfeeding and age under 18 as contraindications (no clinical studies in these groups). Caution in patients with active psychotic disorders (theoretical concern with monoamine modulation).
Drug and Supplement Interactions
Theoretical interactions with anxiolytic medications (benzodiazepines, SSRIs) due to overlapping mechanisms of action. No formal interaction studies have been conducted. Patients on psychotropic medications should consult their physician before adding Selank.
Clinical Perspective
Selank is a peptide that I discuss with patients who are looking for anxiolytic support without the side effects of conventional anxiolytic medications. The Russian clinical data is encouraging, and the mechanistic profile — BDNF modulation, monoamine stabilization, and GABAergic enhancement without direct receptor agonism — is exactly what you would want in an ideal anxiolytic.
The evidence hierarchy matters here. I am transparent with patients that the clinical trial data comes primarily from Russian research institutions and has not been independently replicated in Western clinical trial frameworks. This is not a reason to dismiss the data, but it is a reason to hold it with appropriate caution.
Users of the nasal form commonly describe a calming effect within 15–30 minutes, without the cognitive dulling associated with benzodiazepines. For patients also dealing with cognitive symptoms, Selank may complement approaches discussed in our brain fog treatment guide. These are user reports, not controlled trial outcomes.
What I find most interesting about Selank is its dual anxiolytic-immunomodulatory profile. Many of the patients I see — particularly those with chronic Lyme disease treatment disease or post-COVID syndrome — present with both anxiety and immune dysregulation. A single agent that addresses both dimensions, if the clinical data holds, would be clinically valuable.
I do not position Selank as a replacement for established psychiatric treatment. For patients with severe anxiety disorders, evidence-based psychiatric care remains the standard of care. Selank is an option some people weigh when they prefer to avoid benzodiazepines or who have not responded adequately to conventional approaches.

References
- Zozulia AA, et al. “Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia” (in Russian). Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. PMID: 18454096. https://pubmed.ncbi.nlm.nih.gov/18454096/
- Zozulya AA, et al. “The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity.” Bull Exp Biol Med. 2001;131(4):315-317. PMID: 11550013. https://pubmed.ncbi.nlm.nih.gov/11550013/
- Seredenin SB, et al. “The characteristics of the anxiolytic action of taftsin and its analog TP-7 on behavior and serotonin metabolism” (in Russian). Eksp Klin Farmakol. 1995. PMID: 8704608. https://pubmed.ncbi.nlm.nih.gov/8704608/
- Inozemtseva LS, et al. “Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo.” Dokl Biol Sci. 2008;421:241-243. PMID: 18841804. https://pubmed.ncbi.nlm.nih.gov/18841804/
- Uchakina ON, et al. “Immunomodulatory effects of selank in patients with anxiety-asthenic disorders” (in Russian). Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(5):71-75. PMID: 18577961. https://pubmed.ncbi.nlm.nih.gov/18577961/
- Semenova TP, Kozlovskii II, et al. “Comparison of the effects of selank and tuftsin on the metabolism of serotonin in the brain of rats pretreated with PCPA” (in Russian). Eksp Klin Farmakol. 2009;72(4):6-8. PMID: 19803361. https://pubmed.ncbi.nlm.nih.gov/19803361/
- Selank 0.15% nasal drops, Russian product information (RLS), last updated 15 July 2025. https://www.rlsnet.ru/drugs/selank-2638
Disclaimer: This peptide profile is intended for educational purposes. Selank is approved in Russia but is not approved by the FDA or EMA for any indication. Consult a qualified physician before pursuing any peptide therapy.